Mantle Cell Lymphoma | Specialty

Liso-Cel Shows Encouraging Clinical Activity, Safety in Relapsed/Refractory MCL

March 19th 2021

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

Dr. Martin on Treatment Considerations for MCL

March 17th 2021

Peter Martin, MD, discusses treatment considerations for patients with mantle cell lymphoma.

Dr. Till on the Durability of Response With Brexucabtagene Autoleucel in MCL

March 16th 2021

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Brexucabtagene Autoleucel Displays Continued Durability, Safety in Relapsed/Refractory MCL

March 15th 2021

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

March 12th 2021

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Dr. Martin on the Importance of Developing Novel Therapies in MCL

March 11th 2021

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Neelapu on FDA-Approved CAR T-Cell Products Spanning Lymphoma Subtypes

March 9th 2021

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

Dr. Martin on the Potential Role of LOXO-305 in MCL

March 5th 2021

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Dr. Till on the Potential to Utilize CAR T-Cell Therapy Earlier in MCL

March 4th 2021

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Next Steps in Mantle Cell Lymphoma

March 2nd 2021

MRD Assessment in Mantle Cell Lymphoma

March 2nd 2021

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

March 2nd 2021

Dr. Martin on Potential Combination Strategies With BTK Inhibitors in MCL

March 1st 2021

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm

March 1st 2021

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

Dr. Martin on Potential Drug-Drug Interactions With BTK Inhibitors in MCL

February 26th 2021

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL

February 26th 2021

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

KTE-X19 Continues to Elicit Durable Responses in Relapsed/Refractory MCL

February 24th 2021

February 24, 2021 - The CAR T-cell product KTE-X19 continues to demonstrate durable clinical benefit in patients with relapsed/refractory mantle cell lymphoma, with an overall response rate of 92%.

Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL

February 24th 2021

Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.